Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells

The development of BCR::ABL1 tyrosine kinase inhibitors (TKIs), such as dasatinib, has dramatically improved survival in cases of chronic myeloid leukaemia (CML). However, the development of resistance to BCR::ABL1 TKIs is a clinical problem. BCR::ABL1 TKI resistance is known to have BCR::ABL1‐depen...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsubaki, Masanobu, Takeda, Tomoya, Koumoto, Yuuichi, Usami, Takehiro, Matsuda, Takuya, Seki, Shiori, Sakai, Kazuko, Nishio, Kazuto, Nishida, Shozo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280141/
https://www.ncbi.nlm.nih.gov/pubmed/36847709
http://dx.doi.org/10.1111/cpr.13420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10280141/
https://www.ncbi.nlm.nih.gov/pubmed/36847709
http://dx.doi.org/10.1111/cpr.13420

Ejemplares similares